Several groundbreaking medications are revolutionizing blood sugar treatment, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide standing out leading candidates. Retatrutide, a double GIP and GLP-1 receptor agonist, shows substantial fat reduction coupled with improved glucose control. Cagrillintide, a GLP-1 activator, is presently in me